Trial · NCT00002766

Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma

NCT00002766, Phase 3, Completed, Memorial Sloan Kettering Cancer Center; results first posted 2016-02-22

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma. Trials, record NCT00002766. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00002766

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma
NCT number: NCT00002766
Status: Completed
Phases: Phase 3
Enrollment: 170 participants, actual
Lead sponsor: Memorial Sloan Kettering Cancer Center
Conditions: Leukemia, Lymphoma
Interventions: dactinomycin, sargramostim, carmustine, cyclophosphamide, cytarabine, daunorubicin hydrochloride, doxorubicin hydrochloride, etoposide, mercaptopurine, methotrexate, mitoxantrone hydrochloride, pegaspargase, prednisone, vincristine sulfate, radiation therapy
First posted: 2003-01-27
Last updated: 2016-02-22
Results first posted: 2016-02-22

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Complete Remission (CR)	2 years	complete remission (CR) Disappearance of all clinical evidence of leukemia for a minimum of four weeks. The patient should have a neutrophil count \> 1,000 x 10\^6/1, a platelet count \> 100,000 x 10\^9/1, no circulating blasts, and \< than or = to blasts on bone marrow differential in a qualitatively normal or hypercellular marrow. Progressive disease or failure: Increasing bone marrow infiltrate or development of organ failure or extramedullary infiltrates due to leukemia.

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Complete Remission (CR)	2 years		participants	NUMBER

Source ClinicalTrials.gov

Results by group10

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Units
Complete Remission (CR)	All-2	Complete Remission	50	participants
Complete Remission (CR)	L-20	Complete Remission	50	participants
Complete Remission (CR)	All-2	Complete Response (CR)	14	participants
Complete Remission (CR)	L-20	Complete Response (CR)	11	participants
Complete Remission (CR)	All-2	Failure	5	participants
Complete Remission (CR)	L-20	Failure	14	participants
Complete Remission (CR)	All-2	Failure-Progression	8	participants
Complete Remission (CR)	L-20	Failure-Progression	10	participants
Complete Remission (CR)	All-2	Relapse	1	participants
Complete Remission (CR)	L-20	Relapse	0	participants

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	All-2	81
Overall Study	STARTED	L-20	89
Overall Study	COMPLETED	All-2	78
Overall Study	COMPLETED	L-20	85
Overall Study	NOT COMPLETED	All-2	3
Overall Study	NOT COMPLETED	L-20	4

Source ClinicalTrials.gov

Adverse events180

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Abdominal pain/cramping	Gastrointestinal disorders	All-2	11	81	11
other	Abdominal pain/cramping	Gastrointestinal disorders	L-20	12	89	12
other	Anorexia	General disorders	All-2	6	81	6
other	Anorexia	General disorders	L-20	5	89	5
other	Bilirubin	Metabolism and nutrition disorders	All-2	9	81	9
other	Bilirubin	Metabolism and nutrition disorders	L-20	6	89	6
other	Bone pain	General disorders	All-2	6	81	6
other	Bone pain	General disorders	L-20	0	89	0
other	Dizziness	Nervous system disorders	All-2	7	81	7
other	Dizziness	Nervous system disorders	L-20	6	89	6

1 to 10 of 180Source ClinicalTrials.gov

See all 180 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	All-2
Total, all-cause mortality	L-20
Total, other adverse events	All-2	49	81
Total, other adverse events	L-20	42	89
Total, serious adverse events	All-2	39	81
Total, serious adverse events	L-20	33	89

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
P30CA008748	Cancer Center Support Grant	Rudin, Charles M.	SLOAN-KETTERING INST CAN RESEARCH	NATIONAL CANCER INSTITUTE	1985 to 2026

Source NIH RePORTER

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
All-2 vs L-20: serious adverse events

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00002766

GET https://conductscience.org/api/trials/v1/NCT00002766/events?page=2

API reference For AI assistants